Spots Global Cancer Trial Database for Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Official Title: Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure

Study ID: NCT04677439

Conditions

Flumatinib

Chronic Myeloid Leukemia, Chronic Phase

Imatinib

Interventions

Flumatinib

Study Description

Brief Summary: The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.

Detailed Description: A multicenter, single-arm, prospective, open-label study to detect the efficacy and safety of flumatinib by measuring rates of major molecular response (MMR) at 12 months in CML-CP patients with Ph+ in China. Approximately 200 Patients will be recruited consecutively from the study sites during the enrollment period and will be given flumatinib 600 mg QD. The duration of patient participation will be 24 months.